Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

Trial Profile

An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abaloparatide (Primary) ; Alendronic acid
  • Indications Fracture; Postmenopausal osteoporosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ACTIVExtend
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 01 Nov 2019 Results of post hoc analysis comparing the antifracture efficacy of abaloparatide in ACTIVE with that of alendronate in ACTIVExtend published in the Journal of Clinical Endocrinology and Metabolism
    • 08 May 2019 Results of a post-hoc subset analysis on postmenopausal osteoporosis patients with Type 2 diabetes from the study, presented in a Radius Health financial report.
    • 08 May 2019 According to a Radius Health media release, results of a post-hoc subset analysis on postmenopausal osteoporosis patients with Type 2 diabetes from the study were presented at the American Association of Clinical Endocrinologists conference in April 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top